Patients allocated to atorvastatin had a significant reduction in non-fatal myocardial infarction (MI) and fatal coronary heart disease (CHD) events (HR (95% CI) 0.81 (0.69 to 0.94, p=0.006)), total coronary events (0.88 (0.80 to 0.98, p=0.017)) and CV deaths (0.86 (0.74 to 0.99, p=0.048)). No significant reduction in heart failure (HF), strokes, total CV events and all-cause mortality was observed. Long-term benefits of atorvastatin on the incidence of cardiovascular events: the ASCOT-Legacy 20-year follow-up – https://heart.bmj.com/content/early/2025/03/25/heartjnl-2024-325104
Dr. M. Zann McMahan, thank you.
lifeunderwriter.net 
Cool! I know I have stayed on this for 20 years. Several doctors have suggested I stop, but I didn’t because I had read about its protective effects. Glad I continued.
Me too. When I waned to d/c statins my PCP said OK but I want you in every three months for blood work. I said see you in a year and have not regretted my decision.